R&D
The long-delayed promise of the microbiome, with Sam Possemi...
Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
News
Bayer reveals data behind asundexian's stroke win
Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.
R&D
Strategies for creating an ecosystem to support early-stage ...
Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations
News
Flagship's AI-focused Generate Biomedicines files IPO
Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly asthma drug.
News
Eikon, Veradermics close IPOs, as Salspera joins queue
Eikon and Veradermics push upsized IPOs over the line, as Salspera, which is developing live microbial immunotherapies for cancer, seeks a listing.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
